Miriplatin hydrate

Short Summary : Used in lipiodolization for hepatocellular carcinoma treatment

Category : Membrane Transporter/Ion Channel|Lipophilic platinum complex

Purity : 0.98

CAS Number : 250159-48-9

Formula : C34H70N2O5Pt

Molecular Weight : 782.01

SMILE : CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O.N[C@]1([H])CCCC[C@@]1([H])N.O.[Pt+2]

Solubility : 25℃: DMSO

Storage : Store at -20°C

Description : Description:
IC50 Value: 22.3 microg/ml (7-day exposure, in rat ascites hepatoma AH-109A cells) [2]
Miriplatin was approved for lipiodolization for the treatment of hepatocellular carcinoma in 2009. It is a lipophilic platinum complex containing myristates as leaving groups, and can be easily suspended in ethyl esters of iodized fatty acids obtained from poppy seed oil.
in vitro: In monolayer or suspension cell cultures, SM-11355 did not inhibit the cell growth, whereas SM-11355/Lipiodol had dose-dependent growth inhibitory activities, as did CDDP suspended in Lipiodol (CDDP/Lipiodol) [1]. SM-11355 suspended in Lipiodol (SM-11355/Lipiodol) and CDDP suspended in Lipiodol (CDDP/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. Their IC50 values following 7-day exposure were 22.3 and 0.40 microg/ml, respectively. Following the subsequent 7-day exposure, from day 7 to day 14 after preparation of the suspension, SM-11355/Lipiodol showed an almost equivalent activity, but CDDP/Lipiodol did not show any activity at all [2].
in vivo: Tumor growth was suppressed in the group that received SM-11355 suspended in Lipiodol (SM-11355/Lipiodol). Mean tumor growth rates in the groups administered 20 microl of Lipiodol containing 0, 0.02, 0.04, 0.1, 0.2, or 0.4 mg of SM-11355 were 244, 86, 110, 81, 51, and 40%, respectively, 1 week after treatment [3].
Clinical trial: Launched drug.

Download datasheet